Advanced Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 14, 2024
Abstract
Photodynamic
immunotherapy
which
combines
photodynamic
therapy
with
has
become
an
important
and
effective
method
for
the
treatment
of
cancer.
However,
most
cancer
immunotherapeutic
systems
are
not
able
to
achieve
precise
release
immunomodulators,
resulting
in
systemic
side
effects
poor
patient
outcomes.
Herein,
a
dual‐activatable
nano‐immunomodulator
(DIR
NP),
both
its
effect
agonist
can
be
activated
under
specific
stimuli,
is
reported
precision
immunotherapy.
The
DIR
NP
self‐assembled
from
R848‐conjugated
amphiphilic
polymer
(mPEG‐TK‐R848)
hydrophobic
oxidized
bovine
serum
albumin
(BSA‐SOH)‐conjugatable
photosensitizer
(DIR).
NPs
may
generate
small
amount
1
O
2
808
nm
laser
irradiation,
leading
cleavage
thioketal
(TK)
moiety
R848
DIR.
released
conjugate
tumor‐overexpressed
BSA‐SOH,
improving
efficiency
NIR‐II
fluorescence
signal.
Such
improvement
further
enhance
cargoes
upon
irradiation.
induces
immunogenic
cell
death
(ICD)
immune
factors
maturation
dendritic
cells
inhibiting
growth
primary
distant
tumors
eliminating
lung
metastasis.
Therefore,
this
study
provides
intelligent
regulation
tumor
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 8, 2025
The
therapeutic
efficiency
of
photodynamic
therapy
(PDT)
hinges
on
the
drug-light
interval
(DLI),
yet
conventional
approaches
relying
photosensitizer
accumulation
often
lead
to
suboptimal
irradiation
and
adverse
side
effects.
Here,
a
real-time
cell
death
self-reporting
theranostic
nanoagent
(CDPN)
is
presented
that
dynamically
monitors
extracellular
potassium
ion
([K⁺]ex)
fluctuations
as
direct
indicators
tumor
death.
By
exploiting
[K⁺]ex
dyshomeostasis
associated
with
apoptosis
necrosis,
CDPN
combines
potassium-sensitive
fluorophore
within
mesoporous
silica
nanoparticles,
encapsulated
by
K⁺-selective
membrane
for
enhanced
specificity.
In
vitro
in
vivo
studies
validate
dynamics
closely
correlate
death,
enabling
precise
evaluation
PDT
efficacy
data-driven
optimization
DLI.
Using
breast
cancer
model,
CDPN-guided
adjustments
identify
optimized
DLI
conditions,
achieving
significantly
improved
outcomes.
This
study
introduces
new
paradigm
PDT,
establishing
real-time,
adaptable
strategy
guiding
treatment
parameters
advancing
precision
oncology.
Triple-negative
breast
cancer
(TNBC)
is
one
of
the
most
aggressive
and
challenging
subtypes
with
limited
treatment
options
poor
prognosis.
To
overcome
these
obstacles,
Ag-doped
SnSe
(ASS)
nanosheets
were
used
as
photonic
hyperthermia
agents
for
treating
TNBC.
ASS
featured
a
high
photothermal-conversion
efficiency
photon
effect.
Additionally,
biosafety
assessments,
including
hemolysis
assays
histopathological
analysis,
confirmed
that
was
biosafety.
These
findings
suggest
ASS,
in
synergy
second
near-infrared
biowindow
(NIR-II)
light
irradiation,
offers
noninvasive,
effective,
safe
therapeutic
strategy
This
innovative
approach
exemplifies
evolving
landscape
TNBC
treatment,
where
technology
biology
converge
to
offer
more
precise
personalized
therapies.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 25, 2024
AbstractBackground
Activating
immunogenic
cell
death
(ICD)
represents
a
promising
therapeutic
strategy
for
tumor
immunotherapy.
However,
photodynamic
therapy
(PDT)-mediated
ICD
effects
are
severely
limited
due
to
the
extremely
short
half-life
and
diffusion
radius
of
reactive
oxygen
species
(ROS)
hinder
effective
endoplasmic
reticulum
(ER)
stress
induction.
In
addition,
targeted
triple-negative
breast
cancer
(TNBC)
remain
hugely
challenging
lack
expression
multiple
receptors.
Results
Herein,
we
synthesized
hierarchical
targeting
controllable
intelligent
nanodelivery
material
Da-CD@CET@CQ,
loaded
with
highly
efficient
ER-targeted
photosensitizers
CET
autophagy
inhibitor
chloroquine
(CQ).
Excitingly,
Da-CD@CET@CQ
NPs
can
selectively
target
TNBC
cells
was
effectively
released
in
microenvironment,
enabling
local
accumulation
ER
situ
ROS
production,
which
causing
stronger
amplifying
effect,
further
increasing
immune
suppression
growth.
More
importantly,
CQ
by
inhibit
destroy
damaged
repair,
enhance
anti-tumor
ability
PDT.
Conclusions
Our
findings
indicate
that
reported
novel
photosensitizing
inducer
amplify
combination
inhibition,
provides
meaningful
guideline
PDT
synergistic
immunotherapy
future.
